スポンサーリンク
Division Of Internal Medicine National Cancer Center Hospital | 論文
- What is the most informative pharmacodynamic model for paclitaxel (T)? : a 3 hour-infusion vs. 24-hour infusion.
- Problems with Registration-Directed Clinical Trials for Lung Cancer in Japan
- Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
- Tumor response to chemotherapy : The validity and reproducibility of RECIST guidelines in NSCLC patients
- INHIBITORY EFFECTS OF REPEATED INTRAVENOUS INJECTIONS OF DEXAMETHASONE ON PULMONARY TOXICITY OF A NEW MITOMYCIN C ANALOGUE, KW-2149, IN A NOVEL RAT MODEL
- Inhibitory effects of dexamethasone on pulmonary toxicity of a new mitomycin C analogue KW-2149 in a novel rat model.
- Prospective Evaluation of the Feasibility of Cisplatin-based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ Functions
- Absence of Tumor Promoting Activity of Xylazine in a Two-stage Nasal Carcinogenesis Model in N-bis(2-hydroxypropyl)nitrosamine-treated Rats
- Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: A retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A)
- Phase I Study of Paclitaxel by Three-hour Infusion : Hypotension Just after Infusion Is One of the Major Dose-limiting Toxicities
- MECHANISM OF FK506-INDUCED GLUCOSE INTOLERANCE IN RATS
- Genetic Polymorphisms of Copper- and Platinum Drug-efflux Transporters ATP7A and ATP7B in Japanese Cancer Patients
- Translational and clinical studies of target-based cancer therapy
- Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors
- P7-07 Is emulsification of the test substance with Freund's complete adjuvant(FCA) necessary in the guinea pig maximization test?(IMMUNE AND ALLERGIC SYSTEM/KIDNEYS AND URINARY EXCRETION SYSTEM/CYTOTOXICITY/OTHERS-1)(GENERAL SESSION BY POSTER PRESENTATION
- EFFECTS OF pH AND OSMOLALITY ON PHLEBITIC POTENTIAL OF INFUSION SOLUTIONS FOR PERIPHERAL PARENTERAL NUTRITION
- Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment
- Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer
- A Pharmacokinetic and Pharmacodynamic Analysis of CPT-11 and Its Active Metabolite SN-38
- "P-1 Effects of pH and Osmolality on Phlebitic Potential of infusion Solutions for Peripheral Parenteral Nutrition.